Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 67.33 3.43 (5.37%) Market Cap: 4.14 Bil Enterprise Value: 3.63 Bil PE Ratio: 0 PB Ratio: 349.18 GF Score: 60/100

Rhythm Pharmaceuticals, Inc. - Special Call Transcript

Mar 28, 2019 / 12:30PM GMT
Release Date Price: $29.85 (-0.60%)
Operator

Good morning, and welcome to the Rhythm's Pharmaceuticals' conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I would like to turn the call over to Hannah Deresiewicz with Stern Investment Relations. Please proceed.

Hannah Deresiewicz
Stern Investor Relations, Inc. - Senior Associate

Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for setmelanotide and MC4R Pathway Heterozygous or HET obesity that were announced earlier this morning. You can access the press release for the data as well as the slides that we'll be reviewing today by going to the Investors and Media section of the Rhythm website at www.rhythmtx.com.

With me today with prepared remarks is Dr. Keith Gottesdiener, Chief Executive Officer of Rhythm; Dr. Murray Stewart, Chief Medical Officer; Nithya Desikan, Chief Commercial Officer; and Hunter Smith, Chief Financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot